News

Findings from a recent study suggest that postoperative hemoglobin testing may be safely avoided unless starting hemoglobin is

According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...

A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.

Ciltacabtagene autoleucel demonstrated superior efficacy to physician’s choice of therapy for patients with triple-class exposed, relapsed or refractory multiple myeloma in a recent study.

Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.

Study findings reveal only 33.9% of commercially insured patients with ovarian cancer received germline BRCA testing, despite guideline recommendations.

When compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies may be associated with less health benefits at higher cost, and that the targeted therapies achieve greater benefits at higher cost.

Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...

Researchers conducted an information theoretic network meta-analysis to rank treatment regimens for hormone receptor-positive, ERBB2-negative metastatic breast cancer by their comparative effectiveness.

When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.